DB04999ExperimentalSmall molecule
MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer. AraC's anti-cancer... AraC's anti-cancer activity is associated with its ability to be converted to its biologically active form, araCTP.
- Mechanism
- Curator reviewed
MB07133 is a novel HepDirect prodrug of cytarabine monophosphate designed to produce the oncolytically active form, cytarabine triphosphate, in the liver tumor where it acts to inhibit cell proliferation and induce apoptosis or cell death.
- Primary indication
- Investigated for use/treatment in liver cancer.Curator reviewed
- Code names
- MBO7133
Which companies are running trials of MBO7133, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account